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(calculated from published data). US cost data (2009, dog owner’s perspective) were 
estimated from public sources. Health outcomes were expressed in days without 
symptoms of SP-W-A. All relevant input parameters were varied extensively in one-
way and probabilistic sensitivity analyses, and therapeutic “break points” in costs and 
outcome were determined. RESULTS: Cefovecin was more effective than amoxi/clav 
(162 versus 158 days without symptoms of SP-W-A). Up to a bodyweight (b.w.) of 
31 kg, cefovecin was dominant compared to amoxi/clav ($376.74 versus $382.34 
respectively for dogs with b.w. of 25 kg) when considering total therapy expenditure 
(incl. anamnesis, diagnosis, treatments). In large dogs, cefovecin was more costly; 
however, total therapy costs were only 6% higher than amoxi/clav. Outcomes were 
sensitive to changes of non-compliance, but remained robust when varying other 
parameters. CONCLUSIONS: Considering non-compliance with oral treatments as a 
cause of treatment failure, cefovecin’s higher drug and administration costs are totally 
or substantially offset by its better effectiveness leading to reduced costs for supple-
mentary treatments of relapses and failures.
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OBJECTIVES: To assess the cost-effectiveness of ﬂexible dosing with etanercept 
compared with adalimumab or inﬂiximab treatment in patients with moderate to 
severe psoriasis. METHODS: An economic model was constructed to estimate the 
incremental cost per quality adjusted life year for each therapy compared with no 
systemic therapy (NST). Patients met UK criteria for biologic treatment, which require 
both a Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index 
(DLQI)   10 at baseline. Initial response rates were taken from registration studies 
for each agent: quality of life gain associated with response from patient level data in 
etanercept studies. Adalimumab and inﬂiximab were given continuously in line with 
product licenses. Etancercept can be used ﬂexibly, with some patients experiencing 
drug free intervals between courses of therapy: UK observational data found that 64% 
of etanercept users experience such intervals, with the remainder having continuous 
therapy. Response and withdrawal rates were taken from clinical studies, and extrapo-
lated to a time horizon of 10 years. Costs were estimated from a UK payer perspective 
including drugs, administration visits and hospital stay for treatment failures. Stochas-
tic analysis was undertaken to quantify uncertainty. RESULTS: The model estimated 
incremental cost-effectiveness ratios (ICER) of each therapy compared with NST to 
be: £12,600 (95% CI: £10,131, 14,066) for etanercept ﬂexible dosing; £17,975 
(£17,779, 31,106) for continuous adalimumab and £44,377 (£44,038, 73,815) for 
continuous inﬂiximab. The ICER for etanercept therapy was sensitive to the frequency 
and duration of drug free intervals in these patients but was below the ICER for con-
tinuous therapies. CONCLUSIONS: The model found ﬂexible dosing with etanercept 
to be more cost-effective than continuous therapy, as it allows control to be main-
tained at lower drug cost. This ﬁnding is consistent with a previous publication (Sitzo 
2008), but has now been conﬁrmed with drug utilisation data from UK practice.
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OBJECTIVES: This study aimed to estimate the cost per treatment failure avoided of 
topical preservative-free moxiﬂoxacin (MOXI) as compared with oﬂoxacin (OFLOX), 
marketed as preserved Traﬂoxal and preservative free Traﬂoxal E.D.O.in the treat-
ment of acute infectious conjunctivitis in The Netherlands (NL). METHODS: A survey 
amongst GPs and Ophthalmologists (OPH) collected health care resources(HCU) used 
to manage acute bacterial conjunctivitis. Cost of health care resourses were obtained 
from National databases; treatment failure rates were estimated from a meta-analysis 
of randomized controlled trials(RCT) investigating MOXI. A decision tree model in 
Treeage was populated to deﬁne the cost per treatment failure avoided using MOXI 
instead of OFLOX. OFLOX treatment failure rate was obtained from a trial directly 
comparing OFLOX with MOXI. Probabilistic sensitivity analysis was performed 
investigating the range of HCU used in clinical practice by different OPH and inves-
tigating the uncertainty around treatment failures reduction. RESULTS: The average 
estimated incremental cost per treatment failure avoided by a GP was a53.47 and 
a215a by an OPH (range a169.55a to a279.42). The treatment failure rate for MOXI 
was 2.9% [with 95% CI 1.4%,4.3%] versus 7.6% for OFLOX. The price for MOXI 
taken in the model was a14.04, the maximum reimbursement of current preservative 
free antibiotic treatments in NL. A weighted current average price of Traﬂoxal 
(110,943 units) and Traﬂoxal E.D.O.(15,554 units) was a3.74. With a failure rate less 
than half that for OFLOX, and assuming a willingness to pay (WTP) of 100a per 
treatment failure avoided (based on the WTP for avoiding allergic reactions), in 90% 
of the simulations MOXI is cost-effective. CONCLUSIONS: Use of topical moxiﬂoxa-
cin instead of oﬂoxacin avoids treatment failures. Moxiﬂoxacin, with a price of 14,04a 
is a cost-effective alternative to oﬂoxacin given a willingness to pay of a100 per treat-
ment failure avoided.
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OBJECTIVES: To determine the most cost-effective intravenous antibiotic treatment 
for complicated skin and skin-structure infections (cSSI) in public health care institu-
tions in Mexico. METHODS: A cost-effectiveness study with institutional perspective 
was conducted comparing the use of either i.v. Daptomycin (DAP), i.v. Vancomycin 
(VAN) or i.v. Linezolid (LIN) as ﬁrst-line and/or second-line antibiotic therapy. Data 
was collected from a systematic review which included the most recent published 
articles measuring clinical improvement, length of stay at hospital services and adverse 
events due to the use of any of three alternatives. A decision tree with Bayesian 
approach was designed to simulate the use of resources based on patient’s prognosis 
considering clinical success as the best health state, reached in either short hospital 
stay or long hospital stay, and a therapeutic failure of ﬁrst-line antibiotic therapy 
(DAP, VAN or LIN) which caused the use of a second-line antibiotic therapy (DAP 
or LIN depending on ﬁrst election). Costs calculation considered hospital stay, con-
comitant medication and selected antibiotic treatment. Results were evaluated with 
incremental analysis and one-way sensitivity analysis of the most uncertain variables. 
RESULTS: The use of DAP as ﬁrst-line therapy results in the lowest cost per clinical 
success (CS) (DAP: US$3,405.00/CS; VAN: US$3,550.00/CS; LIN: US$3,870.00/CS). 
In case of therapeutic failure of DAP, the use of LIN as second-line therapy resulted 
in the lowest total cost per clinical success (DAP-LIN: US$3,255.00/CS; VAN-DAP: 
US$3,310.00/CS; VAN-LIN: US$3,310.00/CS; LIN-DAP: US$3,423.00), reaching 
98% of CS. The sensitivity analysis varying clinical success rates of every evaluated 
alternative conﬁrmed the robustness of base study. CONCLUSIONS: Daptomycin is 
the most cost-effective alternative in the treatment of cSSI when used as ﬁrst-line 
antibiotic therapy since its use reduces the length of hospital stay reducing expenses 
of public health system budget in Mexico.
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OBJECTIVES: The purpose was to conduct a cost-effectiveness analysis (CEA) of 
imiquimod therapy compared to no treatment in patients with actinic keratoses (AKs) 
in Poland. METHODS: The analysis was based on a decision model regarding clinical 
effects of imiquimod therapy in comparison to placebo (vehicle cream), determined in 
randomized clinical trials. The population was deﬁned as adult patients with actinic 
keratoses, without hypertrophy and keratosis, with typical course (localisation on 
head skin), competent immune system of patient, when another treatment is contra-
indicated or inappropriate. Complete clearance was assessed as health outcome. Direct 
medical costs of the analyzed therapies were estimated from the perspective of both 
payers in Poland (National Health Fund and patient). Costs of medication and clinic 
visits were included. Time horizon of the analysis was 20 weeks. Treatment was 
assumed as once a day 3x/week, one or two 4-week cycles. Costs and effects were not 
discounted. RESULTS: Ratio of complete clearance was 0.620 for patients treated 
with imiquimod and 0.080 for patients taking placebo. Total costs of imiquimod 
therapy were estimated at 602.26 PLN, while costs of no treatment were 128.26 PLN. 
Incremental cost-effectiveness ratio (ICER) for the comparison of imiquimod versus 
placebo was calculated as 878 PLN per gained complete clearance. CONCLUSIONS: 
Imiquimod is more effective and more expensive than no treatment in patients with 
actinic keratoses. ICER value is below the acceptable threshold, therefore imiquimod 
therapy is considered as cost-effective treatment in Poland.
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OBJECTIVES: Glaucoma is associated with elevated intraocular pressure (IOP) which 
can develop nerve damage and loss of vision. Primary open angle glaucoma (POAG) 
or ocular hypertension (OH) patients should be treated with lowering IOP that is a 
major factor in preventing the progression of visual impairment related to glaucoma. 
Nowadays prostaglandin is recommended as ﬁrst-line treatment drug for reduction of 
elevated IOP. The main objective of this study is to evaluate the cost-effectiveness of 
taﬂuprost compared with latanoprost in POAG or OH patients in Korea. METHODS: 
A decision analytic model was developed from a societal perspective for one year to 
estimate clinical outcome, drug cost and glaucoma related cost. The model assumes 
pathways like following: successful treatment, switching to other drug, adding other 
drug, laser or surgery. Transition probabilities of successful treatment is deﬁned as 
the percentage of patients with elevated IOP achieving 20% reduction, and transition 
probabilities of switching is the percentage of patients who were withdrawn due to 
severe adverse events. IOP reduction rate and transition probabilities were obtained 
from published literatures searched in database. Resource utilizations and costs were 
calculated with Korean national health insurance data and clinical expert opinions. 
Sensitivity analyses were performed on crucial parameters. RESULTS: Taﬂuprost is 
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more effective and less costly than latanoprost (25.68% vs. 24.76% IOP reduction 
rate, $603.08 vs. $615.33 expected cost). Thus taﬂuprost was shown to be dominant 
compared with latanoprost. The results of sensitivity analysis revealed stable across 
most of the included parameters. CONCLUSIONS: According to this study, taﬂuprost 
shows better clinical outcome for one year than latanoprost. In addition, frist-line 
treatment of taﬂuprost is a more cost-effective strategy associated with POAG or 
ocular hypertension compared with latanoprost.
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OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness (CE) 
of biologic drugs for the treatment of moderate to severe psoriasis. METHODS: A 
CE model was developed to estimate the incremental cost per quality adjusted life-year 
(QALY) associated with supportive care and each biologic for the treatment of moder-
ate to severe psoriasis (deﬁned by 4th quartile DLQI for purposes of calculating utili-
ties). Treatments were compared using the Psoriasis Area Severity Index (PASI) 50, 
75, and 90 response rates at 10 weeks for inﬂiximab and 12 weeks for the others, 
which were supported by clinical trials and an expert panel. Direct health care costs 
and utilities values were also included in the analysis. The CE analysis was conducted 
by comparing estimates of expected costs and health effects per unit of time for each 
treatment, incorporating both patients who ‘respond’ and continue treatment and 
those who do not ‘respond’ and stop treatment. All data was reviewed by a focus 
group in order to adapt the model to the Spanish clinical practice RESULTS: In the 
base case analysis inﬂiximab is associated with mean expected costs of a5909 and 
mean expected QALYs of 0.216. Respective results were a2947 and 0.100 QALYs 
for etanercept 25 mg, a5433 and 0.173 QALYs for adalimumab and a7,907 and 0,151 
QALYs for etanercept 50 mg. The incremental cost-effectiveness ratio (ICER) was 
a27,320 for inﬂiximab, a29,430 for etanercept, a31,417 for adalimumab and a52,367 
for etanercept 50 mg. CONCLUSIONS: First Inﬂiximab 5 mg/kg (0,2,6 then every 8 
weeks) and then etanercept 25 mg administered twice a week treatments are the most 
cost-effective alternatives from the Spanish National Health System perspective for the 
treatment of moderate to severe psoriasis, both below the a30,000/QALY threshold 
commonly accepted in Spain for the introduction of new technologies.
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MODEL OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF 
MODERATE TO SEVERE PLAQUE TYPE PSORIASIS
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OBJECTIVES: The objective of the ‘piggy-back’ trial is to examine the cost-effective-
ness of inﬂiximab compared to etanercept in patients with moderate to severe plaque    
psoriasis or psoriasis vulgaris. Before starting the cost-effectiveness study it is usefull 
to know what to measure and where to invest or aim for. The objective of this paper     
is to estimate the expected value of perfect information (EVPI), with an underlying 
goal of estimating the partial EVPI’s (EVPPI’s) to make a prediction about the value 
of obtaining further information, for all parameters and a partial set of parameters. 
METHODS: Analysis was conducted using a Markov model for patients with moder-
ate to severe plaque psoriasis. For estimating partial EVPI’s (EVPPI’s) a Monte Carlo 
simulation (MCS) method was used. Transition probabilities were calculated, based 
on published evidence, expert opinion, and demographic data. Outcomes expected 
were total societal costs, expected QALY’s and clinical effectiveness. The analysis was 
performed from a partial societal perspective of The Netherlands. The outcome of 
partial EVPI was split into costs, utilities, success rates and dropout rates. RESULTS: 
The cost-effectiveness acceptability curve (CEAC) indicates a high decision uncer-
tainty. The CEAC and EVPI also show inﬂiximab needs a high willingness to pay. 
According to the EVPPI analysis the most uncertainty is seen in utilities (25,239 
million) followed by costs (a4,216 million). Success rates and dropout rates also show 
a high EVPPI but much lower (around 204 and 385 million). CONCLUSIONS: When 
looking at the EVPPI’s there is clearly much interest in investing in research to the 
utilities and the cost of treatment and little interest investing in success rates and 
progress rates. Because indirect costs, like costs of travel and productivity loss, are 
excluded and differ between the two therapies, there can be potential gain by further 
research to the costs.
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OBJECTIVES: Biologic therapies have proven efﬁcacious for patients with moderate-
to-severe psoriasis. However, recommended therapeutic regimens and modes of 
administration differ from agent to agent. For Italy, their economic value compared 
with standard of care has not been explored. This study estimates the cost-effectiveness 
of intermittent therapy with etanercept in patients with moderate-to-severe plaque-
type psoriasis in comparison with non-systemic therapy in Italy. METHODS: This 
study employs cost-utility analysis using a Markov model adapted from the British 
“York model”. It compares intermittent etanercept vs non-systemic therapy in terms 
of cost per Quality-Adjusted Life Year (QALY). Data on efﬁcacy and changes in 
quality of life were derived from three etanercept clinical trials. Direct costs of treating 
psoriasis patients, including hospitalizations and dermatology clinic visits, were taken 
from an Italian cost-of-illness study. Extrapolations were made to evaluate the 
cost-effectiveness of intermittent etanercept vs non-systemic therapy over a period of 
ten years. RESULTS: For the group of patients with moderate and severe plaque 
psoriasis (initial Psoriasis Area and Severity Index PASI q 10) the incremental cost-
effectiveness ratio (ICER) for etanercept compared with non-systemic therapy 
was a33,216/QALY; for the group of patients with severe psoriasis (PASI q 20), the 
ICER was a25,486/QALY. CONCLUSIONS: Within the Italian health care system, 
intermittent etanercept (25 mg twice weekly) is a cost-effective therapeutic option 
compared with non-systemic therapy for the group of patients with moderate and 
severe plaque psoriasis. For patients with PASI q 20 etanercept cost-effectiveness is 
even greater.
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OBJECTIVES: To determine the cost-effectiveness of ustekinumab versus etanercept 
among Canadian adults with severe plaque psoriasis who have an inadequate response, 
are intolerant or contraindicated to at least one conventional systemic therapy. 
METHODS: The York Model, developed to evaluate biologics for the National 
Institute for Health and Clinical Excellence, was adapted to the Canadian environ-
ment. The model consisted of an initial 12-week trial period based on results from 
ACCEPT, an active-control phase III trial which demonstrated superior efﬁcacy of 
ustekinumab versus etanercept. The maintenance period, consisted of the trial results 
extrapolated over a 10-year time horizon. The cost-utility analysis compared estimates 
of expected costs and health effects of ustekinumab 45 mg q12w and etanercept 50 mg       
biw for 12 weeks and qw thereafter. Response was deﬁned as achievement of qPASI 
75 from the ACCEPT trial. Non-responders were switched to supportive care. 
Resource utilization was obtained from the literature and a Delphi panel of Canadian 
dermatologists. Direct health care costs were obtained from the literature and expert 
opinion. Utility was mapped from DLQI to EQ-5D using the algorithm used by the 
York Model. Costs and outcomes were discounted at 5%. RESULTS: Mean annual 
costs and QALYs for ustekinumab were $16,835 and 0.1464 compared to $19,558 
and 0.1419 for etanercept. These results were robust to changes in parameter esti-
mates. Not knowing the costs of adverse events over the 10-year time horizon was a 
limitation of the analysis. Cost-effectiveness acceptability curves show that at all levels 
of willingness- to-pay for one additional unit of efﬁcacy, ustekinumab 45 mg remains   
a more cost-effective treatment option than etanercept. CONCLUSIONS: Ustekinumab 
was more effective and less costly than etanercept over a 10-year time horizon, sug-
gesting that ustekinumab is a dominant treatment option relative to etanercept for the 
treatment of patients with severe plaque psoriasis.
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ADHERENCE TO ANTIGLAUCOMA DRUG TREATMENT IN NEWLY 
TREATED PATIENTS
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BACKGROUND: Lack of adherence to drug treatment is a major obstacle to disease 
control. Persistence and compliance are two components of adherence. OBJECTIVES: 
to assess: 1) the proportion of antiglaucoma medication users who persist on their 
treatment after 12 months; 2) the proportion of compliant users among them; and 3) 
the determinants of persistence and of compliance. METHODS: A population-based 
cohort study using the Quebec Health Insurance Board databases. Patients initiated 
on antiglaucoma medication treatment between January 1, 1998, and January 6, 2007 
were included. Patients still undergoing treatment with any antiglaucoma medication 
1 year after their ﬁrst prescription were considered persistent. Of these patients, those 
with a supply of drugs for at least 80% of the days were deemed compliant. A multi-
variate logistic regression model using a stepwise procedure was used to identify the 
characteristics associated with both outcomes. RESULTS: Of 69,461 new users of 
antiglaucoma medication, 41,005 (59%) were persistent after 1 year, and 16,592 
(40.5% of those who persisted) were compliant. Patients more likely to be both per-
sistent and compliant were female and those whose ﬁrst prescription was made by an 
ophthalmologist. Increasing age, living in a rural area, and having initiating glaucoma 
treatment after 2002 were associated with persistence, whereas having used more than 
ﬁve prescription drugs in the year preceding antiglaucoma treatment initiation was 
associated with better compliance. Patients initiated on sympathomimetics, parasym-
pathomimetics, carbonic anhydrase inhibitors, beta blocking agents and on more than 
